A multi-center, randomised study comparing thalidomide and bortezomib for multiple myeloma as maintenance therapy after autologous stem cell transplantatio
Not Applicable
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000003043
- Lead Sponsor
- niversity of Tokyo Hospital, Department of Hematology and Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. Allergy for thalidomide, Bortezomib, mannitol,and boron. 2. A woman during pregnancy or potential pregnancy 3. Patients unable to comply with safety management procedures of thalidomide. 4. Patients who cannot stop drugs or therapy restricted in this trial. 5. Patients who are recognized as inadaptable for this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate 1 year after stem cell transplantation
- Secondary Outcome Measures
Name Time Method Response rate 2 and 3 year after stem cell transplantation. Progression free survival, overall survival, and adverse events.